Common osteoporosis drugs are linked to a 24% lower risk of dementia

What happened

Researchers at the University of Hong Kong (HKUMed) analyzed more than 120,000 older adults and found that people taking nitrogen-containing bisphosphonates, a class of drugs that strengthen bones, developed less dementia. The report’s headline puts it at a 24% lower risk. The drugs, including alendronate and zoledronate, are prescribed to slow bone loss and prevent fractures. The study was published in Alzheimer’s & Dementia.

Why it matters

More than 55 million people live with dementia worldwide today, and the figure could reach 139 million by 2050, according to the text. The first drugs that slow Alzheimer’s are expensive and do not suit every patient. That is why there is interest in repurposing cheap, well-known medicines. A widely used drug that also protected the brain would have a large practical effect.

The number

The authors work with a database of more than 120,000 older adults and stress that the effect was seen in the group that used these drugs.

Context

The same team had earlier shown that osteoporosis and fractures are independent risk factors for dementia, and that people who already have dementia fall and fracture more. Both conditions share factors: advanced age, female sex and low physical activity. That relationship led to the question of whether treating bones could also protect memory. A study of this kind shows an association, not a cause: people who receive these drugs may differ in other habits and conditions that influence the result. On related topics, Mamífero published High-dose flu vaccine and less Alzheimer’s; Coffee and less dementia after 43 years of follow-up; Year-long study links AI companions to lower well-being and Scan-guided statins: same events, fewer prescriptions.

What’s next

To know whether bisphosphonates really protect the brain, controlled trials that assign treatment at random would be needed, along with studies explaining the mechanism. Meanwhile, no one should start or stop a bone treatment because of this result without consulting a doctor.

Bottom line

The hypothesis is attractive because of its low cost, but it remains a hypothesis.

Sources

• ScienceDaily, summary of the University of Hong Kong study published in Alzheimer’s & Dementia (accessed November 9, 2026).
• Cover image: USDAgov, Public domain, via Wikimedia Commons

Edited by Rodrigo Cornejo. How we select and verify: who writes these notes.